Zacks Investment Research upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “

Several other equities research analysts have also weighed in on the stock. BidaskClub upgraded shares of OraSure Technologies from a hold rating to a buy rating in a report on Thursday, December 21st. ValuEngine lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Thursday, November 2nd. Jefferies Group lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity reiterated a buy rating and issued a $22.00 target price on shares of OraSure Technologies in a report on Tuesday, September 19th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $19.65.

OraSure Technologies (NASDAQ OSUR) traded up $0.06 on Tuesday, reaching $19.81. 352,845 shares of the company’s stock traded hands, compared to its average volume of 527,473. The firm has a market capitalization of $1,197.80, a price-to-earnings ratio of 37.98, a PEG ratio of 4.43 and a beta of 1.27. OraSure Technologies has a 12 month low of $8.39 and a 12 month high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period last year, the business posted $0.11 earnings per share. equities research analysts expect that OraSure Technologies will post 0.43 earnings per share for the current year.

In related news, Director Mara G. Aspinall acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the acquisition, the director now directly owns 5,000 shares in the company, valued at approximately $71,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. Pinebridge Investments L.P. acquired a new stake in shares of OraSure Technologies during the second quarter worth $131,000. Oppenheimer Asset Management Inc. acquired a new stake in shares of OraSure Technologies during the third quarter worth $186,000. Victory Capital Management Inc. raised its holdings in shares of OraSure Technologies by 17.6% during the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,360 shares during the period. ARP Americas LLC acquired a new stake in shares of OraSure Technologies during the third quarter worth $221,000. Finally, Noesis Capital Mangement Corp acquired a new stake in shares of OraSure Technologies during the third quarter worth $225,000. Institutional investors and hedge funds own 94.43% of the company’s stock.

WARNING: “OraSure Technologies (OSUR) Upgraded at Zacks Investment Research” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/orasure-technologies-osur-upgraded-at-zacks-investment-research/1805826.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.